Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 12/8/2009
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||0089U / 0||UN / IM|
Administered by: Private Purchased by: Other
Symptoms: Injection site pain, Injection site vesicles
Life Threatening? No
Permanent Disability? No
ER or Doctor Visit? Yes
Other Medications: DEPO-PROVERA; FLAGYL
Preexisting Conditions: Unknown
Diagnostic Lab Data:
CDC 'Split Type': WAES0705USA01113
Write-up:Information has been received from a nurse practitioner concerning an 18 year old white female who on 11-APR-2007 at 15:00 was vaccinated, intramuscularly in the right deltoid, with a first 0.5 ml dose of Gardasil (Lot #655324/0089U). Concomitant therapy included medroxyprogesterone acetate (DEPO-PROVERA) and metronidazole (FLAGYL). On 11-APR-2007, several hours after the vaccination, the patient developed a blister-like reaction at the injection site and at 15:00 experienced prolonged injection site pain (for three weeks). At the time of this report the patient''s outcome for blister-like reaction at injection site was unknown. No product quality complaint was involved. Additional information is not expected.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166